PT - JOURNAL ARTICLE AU - Thomas Reiter AU - Sahra Pajenda AU - Ludwig Wagner AU - Martina Gaggl AU - Johanna Atamaniuk AU - Barbara Holzer AU - Irene Zimpernik AU - Daniela Gerges AU - Katharina Mayer AU - Christof Aigner AU - Robert Straßl AU - Sonja Jansen-Skoupy AU - Manuela Födinger AU - Gere Sunder-Plassmann AU - Alice Schmidt TI - Covid-19 serology in nephrology health care workers AID - 10.1101/2020.07.21.20136218 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.21.20136218 4099 - http://medrxiv.org/content/early/2020/07/26/2020.07.21.20136218.short 4100 - http://medrxiv.org/content/early/2020/07/26/2020.07.21.20136218.full AB - Background Chronic kidney disease patients show a high mortality in case of a SARS-CoV-2 infection. Thus, to be informed on Nephrology personnel’s sero-status might be crucial for patient protection. However, limited information exists about the presence of SARS-CoV-2 antibodies in asymptomatic individuals.Methods We examined the seroprevalence of SARS-CoV-2 IgG and IgM antibodies among health care workers of a tertiary care kidney center during the peak phase of the Covid-19 crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein based assays as well as Western blotting and a neutralization assay.Results At baseline 60 of 235 study participants (25.5%, 95% CI: 20.4-31.5) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity/low specificity threshold in one test system. Follow-up analysis after about two weeks revealed IgG positivity in 12 (5.1%, 95% CI: 2.9-8.8) and IgM positivity in six (2.6%, 95% CI: 1.1-5.6) in at least one assay. 2.1% (95% CI: 0.8-5.0) of health care workers showed IgG nucleocapsid antibodies in at least two assays. By contrast, positive controls with proven Covid-19 showed antibody positivity among almost all test systems. Moreover, serum samples obtained from health care workers did not show SARS-CoV-2 neutralizing capacity, in contrast to positive controls.Conclusions Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.Trial registration number CONEC, ClinicalTrials.gov number NCT04347694Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347694Funding StatementNo funding was granted to this date.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Medical University of Vienna, Registration/Decision Nr. 1357/2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data will be available through the corresponding author.